主页 > 医学动态 >
【drug-news】新类型药物有助于2型糖尿病
New type of drug helpful in type 2 diabetes
Thu Apr 12, 2007 1:34PM BST
Email This Article | Print This Article | RSS
[-] Text [+] NEW YORK (Reuters Health) - Treatment with a drug called anakinra improves blood glucose levels and the secretion of insulin by the beta-cells of the pancreas in patients with type 2 diabetes, new research shows.
Anakinra, also known by the brand name Kineret, blocks an inflammatory compound in the body called interleukin 1 and is usually used to treat arthritis. Lab findings, however, indicate that it might be helpful in people with type 2 diabetes by protecting beta-cells from glucose-induced impairment.
Dr. Marc Y. Donath, from the University Hospital in Zurich, Switzerland, and colleagues assessed the outcomes of 70 patients with type 2 diabetes who were given anakinra or an inactive placebo daily for 13 weeks. The results appear in this week's New England Journal of Medicine.
Patients in the anakinra group achieved an A1C level -- an indicator of long term glucose control -- that was 46 percent lower than that of patients given the placebo.
No serious side effects were observed in anakinra users and none of them developed excessively low blood glucose levels, the researchers point out.
SOURCE: New England Journal of Medicine, April 12, 2007 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 译文
http://uk.reuters.com/article/healthNews/idUKCOL24490420070412
New type of drug helpful in type 2 diabetes
Thu Apr 12, 2007 1:34PM BST
治疗2型糖尿病的新型药物
2007.04.12 周四 英国夏令时下午1：34
[-] Text [+] NEW YORK (Reuters Health) - Treatment with a drug called anakinra improves blood glucose levels and the secretion of insulin by the beta-cells of the pancreas in patients with type 2 diabetes, new research shows.
据路透社纽约健康报道，最新的研究显示，一种名为阿那白滞素（anakinra）的药物可改善2型糖尿病患者的血糖水平，并促进胰岛β细胞释放胰岛素。
Anakinra, also known by the brand name Kineret, blocks an inflammatory compound in the body called interleukin 1 and is usually used to treat arthritis. Lab findings, however, indicate that it might be helpful in people with type 2 diabetes by protecting beta-cells from glucose-induced impairment.
阿那白滞素的商品名为Kineret，体内阻断炎性症介质白介素-1的作用，通常被用于关节炎的治疗。然而，试验结果提示，该药可能保护2型糖尿病患者的β细胞免于高糖引起的损害。
Dr. Marc Y. Donath, from the University Hospital in Zurich, Switzerland, and colleagues assessed the outcomes of 70 patients with type 2 diabetes who were given anakinra or an inactive placebo daily for 13 weeks. The results appear in this week's New England Journal of Medicine.
瑞士苏黎世大学附属医院的Marc Y. Donath博士及其同事对70名2型糖尿病患者连续13周服用阿那白滞素或安慰剂试验的结果进行了评估。试验结果发布于本周新英格兰医学杂志上。
Patients in the anakinra group achieved an A1C level -- an indicator of long term glucose control -- that was 46 percent lower than that of patients given the placebo.
用药组患者血糖水平评价为A1C，即长期血糖控制水平，较安慰剂对照组低46%。
No serious side effects were observed in anakinra users and none of them developed excessively low blood glucose levels, the researchers point out.
研究者指出，用药组患者未见严重不良反应发生，也没有人发展为低血糖。
SOURCE: New England Journal of Medicine, April 12, 2007
译文整理
译文
治疗2型糖尿病的新型药物
2007.04.12 周四 英国夏令时下午1：34
据路透社纽约健康报道，最新的研究显示，一种名为阿那白滞素（anakinra）的药物可改善2型糖尿病患者的血糖水平，并促进胰岛β细胞释放胰岛素。阿那白滞素的商品名为Kineret，体内阻断炎性症介质白介素-1的作用，通常被用于关节炎的治疗。然而，试验结果提示，该药可能保护2型糖尿病患者的β细胞免于高糖引起的损害。瑞士苏黎世大学附属医院的Marc Y. Donath博士及其同事对70名2型糖尿病患者连续13周服用阿那白滞素或安慰剂试验的结果进行了评估。试验结果发布于本周新英格兰医学杂志上。用药组患者血糖水平评价为A1C，即长期血糖控制水平，较安慰剂对照组低46%。研究者指出，用药组患者未见严重不良反应发生，也没有人发展为低血糖。
编者按；
由于没有获得该药品试验剂量，所以无从与其治疗关节炎时的安全性进行相比，也无从评价与其他治疗糖尿病药物间的比较。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-02 05:11
医学,生命科学网